TrialClinical pharmacology and therapeutics2020

Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.

Kathleen Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.